Investing

Dr. Reddy's Laboratories : RDY

RDY

Stock Data

$13.72

$0.08 (0.59%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - SPECIALTY & GENERIC

Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India.

All Dr. Reddy's Laboratories Articles

25 Articles

Trey Thoelcke | Oct 29, 2024 at 10:15 AM EDT

Stock Splits Matter and Here’s What’s Coming Next

Here is a look at why companies split their stocks and why stock splits matter. Plus, upcoming stock splits to…

Chris Lange | Feb 2, 2021 at 12:46 PM EST

Allstate, Cirrus Logic, EA, Zillow and More Tuesday Afternoon Analyst Calls

24/7 Wall St. is looking at some big analyst calls that we have seen so far on Tuesday, including Allstate,…

247sarah | Jun 16, 2020 at 11:38 AM EDT

Why Some Analysts Remain Bullish on Amarin Stock

Is it time to buy Amarin? The biopharmaceutical company just announced a new study showing its drug Vascepa can significantly…

247sarah | Jun 4, 2020 at 12:10 PM EDT

Amarin Stock Is in a Holding Pattern

Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.

247sarah | Jun 2, 2020 at 12:17 PM EDT

Will New Marketing Push Pump Amarin Stock?

Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the…

247sarah | May 27, 2020 at 1:53 PM EDT

Potential COVID-19 Treatment Could Help Amarin Stock

Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent…

Chris Lange | May 22, 2020 at 12:53 PM EDT

Amarin Stock’s Potential Unhampered by Generic Approval

Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.

247sarah | May 19, 2020 at 1:43 PM EDT

Will Amarin Stock’s Fundamentals Outweigh Patent Trial?

Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing…

Chris Lange | May 13, 2020 at 1:48 PM EDT

Huge Sales Growth Brightens Future for Amarin Stock

There are still a lot of questions for Amarin must figure out before it gets back on track. For investors,…

247sarah | May 8, 2020 at 2:02 PM EDT

Why an Appeals Court May Hold Key to Amarin Stock Future

Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that…

Paul Ausick | Apr 28, 2020 at 12:26 PM EDT

Can Amarin Stock Overcome COVID-19 and Legal Headwinds?

Amarin has two big problems. Getting an unfavorable court decision overruled is by far the more important.

Chris Lange | Apr 17, 2020 at 7:30 AM EDT

Is Amarin Stock Doomed After Court Ruling?

Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout.…

Jon C. Ogg | Nov 4, 2019 at 9:00 AM EST

Top Analyst Upgrades and Downgrades: Alibaba, AT&T, BofA, BlackBerry, Boeing, Citigroup, Cloudflare, DocuSign, Lululemon, Marvell, Pinterest, Verizon and More

Monday's top analyst upgrades, downgrades and initiations included Alibaba, AT&T, Bank of America, BlackBerry, Boeing, Citigroup, Cloudflare, DocuSign, Lululemon Athletica,…

Jon C. Ogg | Oct 3, 2018 at 11:45 AM EDT

Why India Continues to Disappoint Investors in 2018

India has been one of the best growth economies measured by gross domestic product for some time, but the secular…

Jon C. Ogg | Nov 29, 2017 at 9:35 AM EST

Why India May Be the Best Place for Investors in 2018 and Beyond

Everyone knows that investors will pay up to chase growth, and it is quite possible that India might be one…